Polyp of gallbladder

Summary

Polyp of gallbladder (MONDO:0021416) is a disease with 5 GWAS associations across 3 studies and 10 clinical trials. Top therapeutic interventions include dexamethasone. A subtype of polyp — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 5
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyp of gallbladder
Mondo ID	MONDO:0021416
ICD-11	839854600
NCIT	C3909
SNOMED CT	197433003
UMLS	C0262493
MedGen	120463
Anatomy (UBERON)	UBERON:0002110
Is cancer (heuristic)	no

Also known as: gall bladder polyp · gallbladder polyp · polyp of the gallbladder

Data availability: 5 GWAS associations (3 studies).

Disease family

This is a subtype of polyp. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › polyp › polyp of gallbladder

Related subtypes (20): epulis, polyp of middle ear, uterine polyp, intestinal polyp, hyperplastic polyp, nasal cavity polyp, stomach polyp, neoplastic polyp, polyp of ureter, polyp of large intestine, polyp of vagina, polyp of vulva, polyp of external auditory canal, polyp of sphenoidal sinus, polyp of frontal sinus, polyp of maxillary sinus, polyp of ethmoidal sinus, polyp of vocal cord, gastrointestinal polyp, fibroepithelial polyp

Subtypes (1): gallbladder adenoma

Genetics & variants

GWAS landscape

5 GWAS associations across 3 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs4507142	2e-13	ABCG8	A	1.18
rs708686	1e-11	FUT6 - FUT3	T	0.3
rs28362459	5e-11	FUT3	C	0.38
rs9843304	4e-10	TM4SF4	T	0.25
rs12152541	6e-10	WDR70P1 - TM4SF4	A	0.34

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90018626	Sakaue S	2021	843	167,459	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90018846	Sakaue S	2021	458	340,083	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90104149	Choe EK	2022	0	0	Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	5
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	2
intergenic_variant	2
missense_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4507142	2	43859452	G>A,C,T	0.05	intron_variant	ABCG8	2e-13	Tier 4: intronic/intergenic
rs708686	19	5840608	C>T	0.05	intergenic_variant	FUT6 - FUT3	1e-11	Tier 4: intronic/intergenic
rs28362459	19	5844781	A>C,G,T	0.3	missense_variant	FUT3	5e-11	Tier 1: coding
rs9843304	3	149493600	C>G,T	0.488	intron_variant	TM4SF4	4e-10	Tier 4: intronic/intergenic
rs12152541	3	149466036	C>A	0.05	intergenic_variant	WDR70P1 - TM4SF4	6e-10	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01383031	PHASE2/PHASE3	UNKNOWN	Safety and Efficacy Study of Transumbilical Laparoendoscopic Single Site Cholecystectomy
NCT06278090	Not specified	ACTIVE_NOT_RECRUITING	Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution
NCT01881399	Not specified	COMPLETED	Fluorescence Versus Intraoperative Cholangiography in the Visualization of Biliary Tree Anatomy
NCT02185586	Not specified	COMPLETED	A Prospective Randomized Controlled Trial of Lower Abdominal Three-port Laparoscopic Cholecystectomy
NCT02224170	Not specified	TERMINATED	Comparison of Effect on Quality of Recovery Outcome Between Systemic Lidocaine and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy
NCT02492685	Not specified	WITHDRAWN	Quantificational Enhancement Pattern Analysis Using a Novel Software Vuebox of Contrast-enhanced Harmonic Endoscopic Ultrasonography for Differential Diagnosis Between Adenomas and Cholesterol Polyps
NCT02762227	Not specified	UNKNOWN	The Role of Different Imaging Methods in the Diagnosis of Gallbladder Polyps
NCT02951169	Not specified	UNKNOWN	Exploration of Standard Surgical Indication in Gallbladder Benign Disease
NCT05715827	Not specified	COMPLETED	A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System
NCT07297225	Not specified	COMPLETED	Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1